24th May 2018

First preventive migraine treatment launches in the US

The Migraine Trust is hoping that it will be approved in the UK in the near future

The world’s first medication to prevent episodic or chronic migraine has launched in the US. This follows its approval last week by the Food and Drug Administration.

Aimovig (erenumab) is one of a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, or CGRP, a molecule that is involved in migraine attacks. Aimovig targets that molecule’s receptor.

Novartis and Amgen have reported successful Aimovig trials with over 3,000 people who experience four to 14 migraine days a month.

While the total of fewer migraine days varied, 40 per cent saw their condition halved or more in frequency.

Some patients saw their migraines eliminated, according to Amgen’s Research Director, Sean Harper.

The Migraine Trust is hoping that it will be approved in the UK in the near future, with NHS accessibility.